Blue Cross NC policies, page 8

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

1,022 public policies Substrate tracks for Blue Cross NC, by title.

Blue Cross NC policies
PolicyDetailsCodesSource
Genetic Testing for CHARGE Syndrome AHS - M2070M2070 · Commercial5Original policy ↗
Genetic Testing for CHARGE Syndrome AHS – M2070M2070 · Commercial1Original policy ↗
Genetic Testing for Connective Tissue Disorders AHS - M2144M2144 · Commercial7Original policy ↗
Genetic Testing for Cystic Fibrosis AHS – M2017M2017 · Commercial64Original policy ↗
Genetic Testing for Cystic Fibrosis AHS – M2017M2017 · Commercial7Original policy ↗
Genetic Testing for Diagnosis of Inherited Peripheral Neuropathies AHS – M2072M2072 · Commercial10Original policy ↗
Genetic Testing for Diagnosis of Inherited Peripheral Neuropathies AHS – M2072M2072 · Commercial8Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial4Original policy ↗
Genetic Testing for Epilepsy AHS – M2075 NotificationM2075 · Commercial10Original policy ↗
Genetic Testing for Familial Alzheimer’s DiseaseAHS – M2038 · Commercial8Original policy ↗
Genetic Testing for Familial Alzheimer’s Disease AHS – M2038M2038 · Commercial7Original policy ↗
Genetic Testing for Familial Alzheimer’s Disease AHS – M2038M2038 · Commercial7Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial6Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial5Original policy ↗
Genetic Testing for Fanconi Anemia AHS – M2077M2077 · Commercial11Original policy ↗
Genetic Testing for Fanconi Anemia AHS – M2077M2077 · Commercial5Original policy ↗
Genetic Testing for FMR1 Mutations AHS – M2028M2028 · Commercial9Original policy ↗
Genetic Testing for FMR1 Mutations AHS – M2028M2028 · Commercial4Original policy ↗
Genetic Testing for Germline Mutations RET Proto-Oncogene Medullary Carcinoma Thyroid AHS-M2078AHS-M2078 · Commercial2Original policy ↗
Genetic Testing for Germline Variants of the RET Proto-Oncogene AHS - M2078M2078 · Commercial4Original policy ↗
Genetic Testing for Hereditary Hearing Loss AHS – G2148G2148 · Commercial11Original policy ↗
Genetic Testing for Hereditary Hemochromatosis AHS – M2012M2012 · Commercial5Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Genetic Testing for Inherited Cardiomyopathies and Channelopathies AHS – M2025M2025 · Commercial17Original policy ↗
Genetic Testing for Lactase Insufficiency AHS – M2080M2080 · Commercial2Original policy ↗
Genetic Testing for Li-Fraumeni Syndrome AHS – M2081M2081 · Commercial4Original policy ↗
Genetic Testing for Li-Fraumeni Syndrome AHS – M2081M2081 · Commercial5Original policy ↗
Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS – M2082M2082 · Commercial1Original policy ↗
Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS – M2082M2082 · Commercial1Original policy ↗
Genetic Testing for Macular Degeneration AHS-M2083AHS-M2083 · Commercial5Original policy ↗
Genetic Testing for Muscular Dystrophies AHS – M2074M2074 · Commercial15Original policy ↗
Genetic Testing for Neurodegenerative Disorders AHS – M2167M2167 · Commercial60Original policy ↗
Genetic Testing for Neurofibromatosis and Related Disorders AHS – M2134M2134 · Commercial19Original policy ↗
Genetic Testing for Ophthalmologic Conditions AHS-M2083AHS-M2083 · Commercial13Original policy ↗
Genetic Testing for Polyposis Syndromes AHS-M2024AHS-M2024 · Commercial9Original policy ↗
Genetic Testing for PTEN Hamartoma Tumor Syndrome AHS – M2087M2087 · Commercial6Original policy ↗
Genetic Testing for PTEN Hamartoma Tumor Syndrome AHS – M2087M2087 · Commercial4Original policy ↗
Genetic Testing for Rett Syndrome AHS – M2088M2088 · Commercial7Original policy ↗
Genetic Testing for Rett Syndrome AHS – M2088M2088 · Commercial6Original policy ↗
Genetic Testing of CADASIL Syndrome AHS – M2069M2069 · Commercial3Original policy ↗
Genetic Testing of CADASIL Syndrome AHS – M2069M2069 · Commercial2Original policy ↗
Genetic Testing of Mitochondrial Disorders AHS – M2085M2085 · Commercial22Original policy ↗
Genetic Tests: Once per LifetimeG-23002 · Effective Oct 1, 2025 · Medicaid—Original policy ↗
Genicular Nerve Blocks and Peripheral Nerve Ablation for Knee Pain4Original policy ↗
Genome and Exome Sequencing AHS – M2032M2032 · Commercial30Original policy ↗
Genome and Exome Sequencing AHS – M2032 NotificationM2032 · Commercial30Original policy ↗
Genomic Testing for Hematopoietic Neoplasms AHS- M2182AHS-M2182 · Commercial29Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.